Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.



from The Medical News http://ift.tt/1A6ZONY